Biotech News

Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption

Humacyte (HUMA)HumacyteEarnings

– Commercial adoption of Symvess® accelerated during the third quarter with sales totaling $1.0 million, a 151% increase over the 2 nd quarter. – Symvess commercial momentum continued into the fourth quarter, with October 2026 sales totaling $0.8 million.

Related news

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

Stock data

Close
0.54 USD
Market cap
308.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States